Marco Santucci

Marco Santucci

Auto-generated profile, based on publicly available information

Marco Santucci

University of Florence, School of Human Health Sciences

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2005 in Blood
Verified
Journal Article
Closed access
PDF file
RWRein Willemze
Rein Willemze
EJElaine S Jaffe
Elaine S Jaffe
GBGünter Burg
Günter Burg
LCLorenzo Cerroni
Lorenzo Cerroni
EBEmilio Berti
Emilio Berti
CMChris J L M Meijer
Chris J L M Meijer
Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, but both systems have shortcomings. In particular, differences in the classification of cutaneous T-cell lymphomas other than mycosis fungoides, Sézary syndrome, and the group of primary cutaneous CD30+ lymphoproliferative disorders and the classification and terminology of different types of cutaneous B-cell lymphomas have resulted in considerable debate and confusion. During recent consensus meetings representatives of both systems reached agreement on a new classification, which is now called the WHO-EORTC classification. In this paper we describe the characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin, and discuss differences with the previous classification schemes. In addition, the relative frequency and survival data of 1905 patients with primary cutaneous lymphomas derived from Dutch and Austrian registries for primary cutaneous lymphomas are presented to illustrate the clinical significance of this new classification.

15 January 2008 in Blood
Verified
Journal Article
Open access
PDF file
RWRein Willemze
Rein Willemze
PJPatty M. Jansen
Patty M. Jansen
LCLorenzo Cerroni
Lorenzo Cerroni
EBEmilio Berti
Emilio Berti
MSMarco Santucci
Marco Santucci
CMChris J. L. M. Meijer
Chris J. L. M. Meijer
In the WHO classification, subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behavior. Recent studies suggest that distinction should be made between SPTL with an α/β T-cell phenotype (SPTL-AB) and SPTL with a γδ T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-ABs and 20 SPTL-GDs were studied at a workshop of the EORTC Cutaneous Lymphoma Group. SPTL-ABs were generally confined to the subcutis, had a CD4−, CD8+, CD56−, βF1+ phenotype, were uncommonly associated with a hemophagocytic syndrome (HPS; 17%), and had a favorable prognosis (5-year overall survival [OS]: 82%). SPTL-AB patients without HPS had a significantly better survival than patients with HPS (5-year OS: 91% vs 46%; P < .001). SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4−, CD8−, CD56+/−, βF1− T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment. These results indicate that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further be used only for SPTL-AB. SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned.

1 December 2005 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
NPNicola Pimpinelli
Nicola Pimpinelli
EOElise A. Olsen
Elise A. Olsen
MSMarco Santucci
Marco Santucci
EVEric Vonderheid
Eric Vonderheid
AHAndreas C. Haeffner
Andreas C. Haeffner
GWGary S. Wood
Gary S. Wood

16 November 2005 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
GBGünter Burg
Günter Burg
WKWerner Kempf
Werner Kempf
ACAntonio Cozzio
Antonio Cozzio
JFJosef Feit
Josef Feit
RWRein Willemze
Rein Willemze
SWSean Whittaker
Sean Whittaker

17 January 2003 in Cancer
Verified
Journal Article
Open access
PDF file
MSMarco Santucci
Marco Santucci
NPNicola Pimpinelli
Nicola Pimpinelli
DMDaniela Massi
Daniela Massi
MKMarshall E. Kadin
Marshall E. Kadin
CMChris J. L. M. Meijer
Chris J. L. M. Meijer
EBEmilio Berti
Emilio Berti
BACKGROUND: Cutaneous lymphomas expressing a cytotoxic or natural killer (NK) cell phenotype represent a group of lymphoproliferative disorders for which there is currently much confusion and little consensus regarding the best nomenclature and classification.METHODS: This study analyzes 48 cases of primary cutaneous lymphoma expressing cytotoxic proteins and/or the NK cell marker, CD56. These cases were collected for a workshop of the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Task Force, to better clarify the clinical, morphologic, and phenotypic features of these uncommon tumors.RESULTS: Several categories with different clinical and pathologic features were delineated: 1) aggressive, CD8+, epidermotropic, cytotoxic T‐cell lymphoma; 2) mycosis fungoides, cytotoxic immunophenotype variant; 3) subcutaneous panniculitis‐like T‐cell lymphoma; 4) NK/T‐cell lymphoma, nasal type; 5) CD4+, NK cell lymphoma; 6) blastoid NK cell lymphoma; (7) intravascular NK‐like lymphoma; and 8) cytotoxic, peripheral T‐cell lymphoma.CONCLUSIONS: Our data show that primary cutaneous cytotoxic/NK cell lymphomas include distinct groups of diseases, clinically, histologically, and biologically. Because the finding of a cytotoxic phenotype often has prognostic significance, the routine use of cytotoxic markers in the diagnosis and classification of cutaneous lymphomas should be expanded. Cancer 2003;97:610–27. © 2003 American Cancer Society.DOI 10.1002/cncr.11107

1 May 1991 in Cancer
Verified
Journal Article
Closed access
PDF file
MSMarco Santucci
Marco Santucci
NPNicola Pimpinelli
Nicola Pimpinelli
LALuisa Arganini
Luisa Arganini